Robert Wanerman’s Theranos Analysis Showcased in General Counsel NewsGeneral Counsel News July 29, 2016
Robert E. Wanerman, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, authored an article that was showcased in General Counsel News titled “Disruptor Meets Regulator, and Regulator Wins: Lessons Learned from Theranos.”
Following is an excerpt:
Although Theranos’s history — which includes several administrative penalties for the troubled blood-testing company — has received an outsize amount of media attention, its experience with regulatory agencies highlights several important issues for start-up and emerging health care entities, writes Robert E. Wanerman in Epstein Becker & Green‘s Health Law Advisor blog.
He discusses four major questions raised in this type of case, with these headings: What Do Regulators Want?, What Do Health Care Providers and Payors Want?, Who Is Investing in the Venture?, and Who’s on Board?
This article was first published in Health Law Advisor, an Epstein Becker Green blog.